Which has stronger valuation and earnings, TECH or RGEN?

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Techne $1.22B 9.35 $181.86M $1.15 62.97 Repligen $738.26M 12.87 $48.89M $0.73 230.55

Is TECH or RGEN more profitable?

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Bio-Techne 14.97% 13.23% 10.61% Repligen 5.29% 5.30% 3.79%

Does the media refer more to TECH or RGEN?

In the previous week, Repligen had 1 more articles in the media than Bio-Techne. MarketBeat recorded 14 mentions for Repligen and 13 mentions for Bio-Techne. Repligen's average media sentiment score of 1.52 beat Bio-Techne's score of 1.36 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Techne 11 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Repligen 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer RGEN or A?

In the previous week, Agilent Technologies had 17 more articles in the media than Repligen. MarketBeat recorded 31 mentions for Agilent Technologies and 14 mentions for Repligen. Repligen's average media sentiment score of 1.52 beat Agilent Technologies' score of 1.11 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Agilent Technologies 18 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, BIO or RGEN?

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bio-Rad Laboratories $2.58B 3.99 $759.90M $8.25 46.72 Repligen $738.26M 12.87 $48.89M $0.73 230.55

Does the media favor BIO or RGEN?

In the previous week, Repligen had 10 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 14 mentions for Repligen and 4 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.52 beat Bio-Rad Laboratories' score of 0.50 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bio-Rad Laboratories 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable valuation and earnings, RGEN or DHR?

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Repligen $738.26M 12.87 $48.89M $0.73 230.55 Danaher $24.57B 5.93 $3.61B $5.63 36.79

Is RGEN or DHR more profitable?

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity. Company Net Margins Return on Equity Return on Assets Repligen 5.29% 5.30% 3.79% Danaher 15.95% 11.04% 6.81%

Does the media favor RGEN or DHR?

In the previous week, Danaher had 16 more articles in the media than Repligen. MarketBeat recorded 30 mentions for Danaher and 14 mentions for Repligen. Repligen's average media sentiment score of 1.52 beat Danaher's score of 1.52 indicating that Repligen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Repligen 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Danaher 26 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor MTD or RGEN?

In the previous week, Mettler-Toledo International had 13 more articles in the media than Repligen. MarketBeat recorded 27 mentions for Mettler-Toledo International and 14 mentions for Repligen. Repligen's average media sentiment score of 1.52 beat Mettler-Toledo International's score of 1.27 indicating that Repligen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mettler-Toledo International 17 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Repligen 12 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Repligen (RGEN) Competitors

$168.07 -1.54 (-0.91%)

As of 02:09 PM Eastern

Compare

RGEN vs. TECH, A, BIO, DHR, and MTD

Should you buy Repligen stock or one of its competitors? Repligen's main competitors and comparable companies include Bio-Techne (TECH), Agilent Technologies (A), Bio-Rad Laboratories (BIO), Danaher (DHR), and Mettler-Toledo International (MTD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does Repligen compare to Bio-Techne?

Bio-Techne (NASDAQ:TECH) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Bio-Techne has a beta of 1.28, indicating that its share price is 28% more volatile than the broader market. Comparatively, Repligen has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Bio-Techne currently has a consensus target price of $68.92, indicating a potential downside of 4.82%. Repligen has a consensus target price of $166.43, indicating a potential downside of 1.11%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Techne	0 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.12
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

99.0% of Bio-Techne shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 1.3% of Bio-Techne shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Repligen had 1 more articles in the media than Bio-Techne. MarketBeat recorded 14 mentions for Repligen and 13 mentions for Bio-Techne. Repligen's average media sentiment score of 1.52 beat Bio-Techne's score of 1.36 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Techne	11 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Repligen	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Bio-Techne has higher revenue and earnings than Repligen. Bio-Techne is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Techne	$1.22B	9.35	$181.86M	$1.15	62.97
Repligen	$738.26M	12.87	$48.89M	$0.73	230.55

Bio-Techne has a net margin of 14.97% compared to Repligen's net margin of 5.29%. Bio-Techne's return on equity of 13.23% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Techne	14.97%	13.23%	10.61%
Repligen	5.29%	5.30%	3.79%

Summary

Bio-Techne beats Repligen on 9 of the 17 factors compared between the two stocks.

How does Repligen compare to Agilent Technologies?

Repligen (NASDAQ:RGEN) and Agilent Technologies (NYSE:A) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

97.6% of Repligen shares are held by institutional investors. 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Agilent Technologies has higher revenue and earnings than Repligen. Agilent Technologies is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	12.87	$48.89M	$0.73	230.55
Agilent Technologies	$6.95B	6.12	$1.30B	$5.08	29.69

Repligen presently has a consensus price target of $166.43, suggesting a potential downside of 1.11%. Agilent Technologies has a consensus price target of $170.33, suggesting a potential upside of 12.94%. Given Agilent Technologies' higher possible upside, analysts clearly believe Agilent Technologies is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Agilent Technologies	0 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Agilent Technologies had 17 more articles in the media than Repligen. MarketBeat recorded 31 mentions for Agilent Technologies and 14 mentions for Repligen. Repligen's average media sentiment score of 1.52 beat Agilent Technologies' score of 1.11 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Agilent Technologies	18 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Repligen has a beta of 1.05, meaning that its share price is 5% more volatile than the broader market. Comparatively, Agilent Technologies has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to Repligen's net margin of 5.29%. Agilent Technologies' return on equity of 24.45% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Agilent Technologies	19.53%	24.45%	13.09%

Summary

Agilent Technologies beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Repligen compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, institutional ownership, media sentiment and profitability.

Bio-Rad Laboratories has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market. Comparatively, Repligen has a beta of 1.05, indicating that its stock price is 5% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 8.59% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Bio-Rad Laboratories' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	8.59%	3.54%	2.48%
Repligen	5.29%	5.30%	3.79%

Bio-Rad Laboratories has higher revenue and earnings than Repligen. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.99	$759.90M	$8.25	46.72
Repligen	$738.26M	12.87	$48.89M	$0.73	230.55

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bio-Rad Laboratories presently has a consensus price target of $343.33, suggesting a potential downside of 10.93%. Repligen has a consensus price target of $166.43, suggesting a potential downside of 1.11%. Given Repligen's stronger consensus rating and higher possible upside, analysts plainly believe Repligen is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.20
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

In the previous week, Repligen had 10 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 14 mentions for Repligen and 4 mentions for Bio-Rad Laboratories. Repligen's average media sentiment score of 1.52 beat Bio-Rad Laboratories' score of 0.50 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bio-Rad Laboratories	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Repligen beats Bio-Rad Laboratories on 11 of the 17 factors compared between the two stocks.

How does Repligen compare to Danaher?

Repligen (NASDAQ:RGEN) and Danaher (NYSE:DHR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

97.6% of Repligen shares are owned by institutional investors. Comparatively, 79.1% of Danaher shares are owned by institutional investors. 0.6% of Repligen shares are owned by company insiders. Comparatively, 10.8% of Danaher shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Danaher has a net margin of 15.95% compared to Repligen's net margin of 5.29%. Danaher's return on equity of 11.04% beat Repligen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Repligen	5.29%	5.30%	3.79%
Danaher	15.95%	11.04%	6.81%

Danaher has higher revenue and earnings than Repligen. Danaher is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Repligen	$738.26M	12.87	$48.89M	$0.73	230.55
Danaher	$24.57B	5.93	$3.61B	$5.63	36.79

Repligen presently has a consensus target price of $166.43, suggesting a potential downside of 1.11%. Danaher has a consensus target price of $228.91, suggesting a potential upside of 10.52%. Given Danaher's higher probable upside, analysts plainly believe Danaher is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00
Danaher	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.84

Repligen has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market. Comparatively, Danaher has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, Danaher had 16 more articles in the media than Repligen. MarketBeat recorded 30 mentions for Danaher and 14 mentions for Repligen. Repligen's average media sentiment score of 1.52 beat Danaher's score of 1.52 indicating that Repligen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Repligen	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Danaher	26 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Danaher beats Repligen on 10 of the 17 factors compared between the two stocks.

How does Repligen compare to Mettler-Toledo International?

Mettler-Toledo International (NYSE:MTD) and Repligen (NASDAQ:RGEN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, media sentiment, risk, institutional ownership and earnings.

Mettler-Toledo International currently has a consensus price target of $1,445.31, suggesting a potential upside of 6.63%. Repligen has a consensus price target of $166.43, suggesting a potential downside of 1.11%. Given Mettler-Toledo International's higher possible upside, equities analysts plainly believe Mettler-Toledo International is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mettler-Toledo International	1 Sell rating(s)	8 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.33
Repligen	0 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	3.00

Mettler-Toledo International has a net margin of 21.91% compared to Repligen's net margin of 5.29%. Repligen's return on equity of 5.30% beat Mettler-Toledo International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mettler-Toledo International	21.91%	-1,212.14%	25.11%
Repligen	5.29%	5.30%	3.79%

Mettler-Toledo International has higher revenue and earnings than Repligen. Mettler-Toledo International is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mettler-Toledo International	$4.03B	6.75	$869.19M	$44.43	30.51
Repligen	$738.26M	12.87	$48.89M	$0.73	230.55

Mettler-Toledo International has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Repligen has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

In the previous week, Mettler-Toledo International had 13 more articles in the media than Repligen. MarketBeat recorded 27 mentions for Mettler-Toledo International and 14 mentions for Repligen. Repligen's average media sentiment score of 1.52 beat Mettler-Toledo International's score of 1.27 indicating that Repligen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mettler-Toledo International	17 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Repligen	12 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

95.1% of Mettler-Toledo International shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 0.7% of Mettler-Toledo International shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Mettler-Toledo International beats Repligen on 9 of the 17 factors compared between the two stocks.

Get Repligen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RGEN vs. The Competition

Export

Metric	Repligen	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.49B	$9.95B	$7.19B	$12.89B
Dividend Yield	N/A	1.46%	2.53%	8.57%
P/E Ratio	230.37	65.05	272.97	25.41
Price / Sales	12.87	112.23	619.91	98.79
Price / Cash	50.61	26.86	77.82	52.27
Price / Book	4.50	36.25	12.87	6.18
Net Income	$48.89M	$56.67B	$3.47B	$349.63M
7 Day Performance	-4.52%	-0.90%	1.11%	-0.02%
1 Month Performance	12.37%	4.51%	5.69%	0.85%
1 Year Performance	39.58%	26.50%	25.57%	15.50%

Repligen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RGEN Repligen	3.2905 of 5 stars	$168.07 -0.9%	$166.43 -1.0%	+46.0%	$9.47B	$738.26M	229.89	2,000	Positive News
TECH Bio-Techne	3.4653 of 5 stars	$72.31 -0.1%	$68.92 -4.7%	+35.8%	$11.35B	$1.22B	62.88	3,000	Positive News
A Agilent Technologies	4.8635 of 5 stars	$153.79 0.0%	$170.33 +10.8%	+19.8%	$43.45B	$6.95B	30.27	18,100	Positive News Options Volume
BIO Bio-Rad Laboratories	1.6849 of 5 stars	$386.68 -0.3%	$343.33 -11.2%	+35.0%	$10.37B	$2.58B	46.87	7,450	News Coverage
DHR Danaher	4.5979 of 5 stars	$213.90 -1.0%	$228.91 +7.0%	+5.7%	$151.89B	$24.57B	37.99	60,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RGEN) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Summary

How does Repligen compare to Agilent Technologies?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Summary

How does Repligen compare to Danaher?

Summary

How does Repligen compare to Mettler-Toledo International?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Repligen (RGEN) Competitors

RGEN vs. TECH, A, BIO, DHR, and MTD

How does Repligen compare to Bio-Techne?

Which has more volatility & risk, TECH or RGEN?

Do analysts recommend TECH or RGEN?

Do insiders and institutionals believe in TECH or RGEN?

Does the media refer more to TECH or RGEN?

Which has stronger valuation and earnings, TECH or RGEN?

Is TECH or RGEN more profitable?

Summary

How does Repligen compare to Agilent Technologies?

Do insiders & institutionals hold more shares of RGEN or A?

Which has preferable valuation & earnings, RGEN or A?

Do analysts rate RGEN or A?

Does the media prefer RGEN or A?

Which has more volatility & risk, RGEN or A?

Is RGEN or A more profitable?

Summary

How does Repligen compare to Bio-Rad Laboratories?

Which has more volatility & risk, BIO or RGEN?

Is BIO or RGEN more profitable?

Which has higher valuation & earnings, BIO or RGEN?

Do institutionals and insiders hold more shares of BIO or RGEN?

Do analysts rate BIO or RGEN?

Does the media favor BIO or RGEN?

Summary

How does Repligen compare to Danaher?

Do institutionals & insiders hold more shares of RGEN or DHR?

Is RGEN or DHR more profitable?

Which has preferable valuation and earnings, RGEN or DHR?

Do analysts prefer RGEN or DHR?

Which has more volatility & risk, RGEN or DHR?

Does the media favor RGEN or DHR?

Summary

How does Repligen compare to Mettler-Toledo International?

Do analysts prefer MTD or RGEN?

Is MTD or RGEN more profitable?

Which has stronger earnings & valuation, MTD or RGEN?

Which has more risk and volatility, MTD or RGEN?

Does the media favor MTD or RGEN?

Do insiders & institutionals hold more shares of MTD or RGEN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RGEN vs. The Competition

Repligen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools